Scholarly Works - Book sections
Book section
·
November 4, 2024
Most patients with prostate adenocarcinoma develop resistance to therapies targeting the androgen receptor (AR). Consequently, a portion of these patients develop AR-independent neuroendocrine (NE) prostate cancer (NEPC), a rapidly progressing cancer with ...
Full text
Link to item
Cite
Book section
·
December 1, 2010
The standard first-line treatment for metastatic castration-resistant prostate cancer (CRPC) is docetaxel chemotherapy. Platinum drugs, including cisplatin and carboplatin, when used as single agents and in combinations, have shown a moderate response in m ...
Full text
Cite
https://orcid.org/0000-0003-1195-1998